# Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

> **NCT02470299** · NA · COMPLETED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 21 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Ketorolac
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02470299
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-29
- **Primary completion:** 2018-10-08
- **Final completion:** 2024-01-25
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02470299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02470299, "Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02470299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*